Mizuho Securities analyst Difei Yang reiterated a Buy rating on NovoCure (NASDAQ:NVCR) Ltd on Monday, setting a price target of $175, which is approximately 40.49% above the present share price of $124.56.
Yang expects NovoCure Ltd to post earnings per share (EPS) of $0.05 for the first quarter of 2021.
The current consensus among 8 TipRanks analysts is for a Moderate Buy rating of shares in NovoCure, with an average price target of $160.57.
The analysts price targets range from a high of $225 to a low of $103.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $143.95 million and a net profit of $12.09 million. The company's market cap is $12.76 billion.
According to TipRanks.com, Mizuho Securities analyst Difei Yang is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -7.3% and a 30.48% success rate.
NovoCure Ltd. develops treatment for tumors. Its platform is called the Tumor Treating Field which used electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.